Catalyst Wire Dossier Catalyst Wire Dossier

Nucresiran

Nucresiran · Alnylam Pharmaceuticals
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Nucresiran, covering 2026-04-17 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy [Phase 3]

See pricing